April 30th 2024
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM
March 29th 2021Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.
Watch
Orca-T Reduces GVHD, Mortalities in Hematologic Malignancies
March 28th 2021Data presented during the 2021 Transplantation and Cellular Therapy Meetings showed that treatment with Orca-T achieved a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, and a lack of treatment-related mortalities while demonstrating scalability potential.
Read More
FDA Approves Ide-Cel for Relapsed/Refractory Multiple Myeloma
March 27th 2021The FDA has approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
Read More
The REACH2 Study in Steroid-Refractory Acute GVHD
March 22nd 2021Dr Michael Bishop, of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, describes the rationale for the design of the phase 3 REACH2 trial in steroid-refractory acute graft-versus-host disease and provides perspective on important takeaways from data presented.
Watch
Steroid-Refractory Acute Graft-Versus-Host Disease Defined
March 22nd 2021Michael Bishop, MD, shares recommendations that can help hematologists/oncologists appropriately identify patients with steroid-refractory acute graft-versus-host disease and describes how his treatment approaches differ based on grade.
Watch
Clinical Benefit Demonstrated With Ublituximab Plus Ibrutinib in R/R CLL
March 15th 2021Patients with relapsed or refractory high-risk chronic lymphocytic leukemia achieved a statistically higher rate of overall response when the glycoengineered, type I anti-CD20 monoclonal antibody ublituximab was added to the Bruton’s tyrosine kinase inhibitor ibrutinib, according to results from the phase 3 GENUINE study.
Read More
FDA Postpones Approval Decision on Belumosudil for Chronic Graft-Versus-Host Disease
March 12th 2021The FDA has extended the review period for the New Drug Application for belumosudil, which is being considered as a potential treatment option for patients with chronic graft-versus-host disease.
Read More
A 50-Year-Old Woman With Steroid-Refractory Acute Graft Versus Host Disease
March 12th 2021Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.
Watch
FDA Approves Axi-Cel for Relapsed/Refractory Follicular Lymphoma in Third-Line or Beyond
March 6th 2021The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
Read More
Blinatumomab Improves Survival Outcomes Over Chemotherapy in High-Risk B-ALL
March 3rd 2021Blinatumomab consolidation demonstrated significantly prolonged event-free survival in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia when compared with chemotherapy before allogeneic hematopoietic stem cell transplantation.
Read More
FDA Grants Priority Review to Ruxolitinib in Steroid-Refractory cGVHD
February 23rd 2021The FDA has accepted a supplemental New Drug Application for ruxolitinib and granted it Priority Review as a potential treatment option for adult and pediatric patients 12 years and older with steroid-refractory chronic graft-versus-host disease.
Read More